Description

Work done in WP5 is multi-facetted and aims by different means to increase visibility of research institutions in Latvia (RSU) and Ukraine (KIEPOR) to international research community. WP5 targets broad public, whereas a wide span of the science-oriented outreach and dissemination activities integrated into WP1-WP4 are researcher-audience oriented.

Creation and support of the Consortium website

The main effort is the creation and support of the Consortium website. VACTRAIN website will give information about objectives, describe past, on-going and planned educational activities, monitor their progress, publish reports on the seminars, workshops and trainings up-to individual presentations of the speakers/trainers. On the overall, it will make VACTRAIN transparent and attractive to the scientific community as well as to the general public. Through this web-site, all information about the coming VACTRAIN activities will be spread to the project participants and to other interested researchers in Latvia, Ukraine and abroad. Web-site will be created in English, with partial translation of the main activities into Latvian and Ukrainian to satisfy the interest of gymnasium and bachelor students, for further potential attraction into the biomedicine field, and to satisfy the interest of the general public with possibility of crowd-funding. The lead partner in dissemination and out-reaching activities is MTC/KI (8 PM)

Connecting to other researchers

An important dissemination and out-reaching activity is the establishment and continuous support of interactions with other research Networks active in the field, such as Baltinfect at RSU; The European Epstein-Barr Virus (EBV) Association, Baltic Network against Life-threatening Viral Infections (Baltic Antiviral Network; BAN; MTC/KI), other research networks at Karolinska Institutet as “KI Cancer”, “Swedish Society of Immunology”, TORNADO Consortium (Molecular Targets Open for Regulation by the gut flora – New Avenues for improved Diet to Optimize European health). Responsible for contacts will be partner RSU (2 PM). Another form of dissemination will be oral and poster presentations of the objectives and achievements of VACTRAIN on the main international research meetings in tumor biology, oncology and vaccines & vaccination (Responsible partner KIEPOR). Last but not the least are the scientific publications and presentations of the Consortium members on the research conferences in the field of the proposed research which would be the responsibility of the respective team leaders, not funded by TWINNING.

Out-reaching to general public

VACTRAIN will address the non-researcher audience to draw attention to the success if novel vaccination platforms, as naked DNA vaccines, and to the importance of the development of novel approaches in the therapy of cancer, noninvasive, nontoxic, applicable to a wide variety of tumors, with the aim to increase awareness, form public opinion, recruit support, and possibly initiate fund raising. This will be done by out-reaching through Newspapers, magazine, TV and internet briefs with at least two annual presentations. The lead partner in dissemination and out-reaching activities is MTC/KI. Besides, flyers and brochures will be prepared describing VACTRAIN content and on-going activities will be annually prepared, printed and distributed on the research meetings of different levels to create the awareness of VACTRAIN (Responsible partners RSU and DGB/LU).

Dissemination of the educational materials Project web-site, flyers, brochures will be used to disseminate a vast bulk of educational materials accumulated during the fulfillment of the project, namely power point presentations of lectures, seminars, tutorials, curriculums for laboratory trainings, and tests/exams. The materials will be open for re-use internal as well as external parties (Responsible partners RSU, MTC/KI, DGB/LU, KIEPOR).

Analysis of the field of immunotherapy with focus on cancer

Analysis of the field of immunotherapy, specifically of cancer will be done for positioning of VACTRAIN future research efforts. The outcome will be technology report on modern approaches to immunotherapy/therapeutic vaccination and their application to treatment of cancer (M24) in the form of scientific review and popular science review for mass media.